Analysis: Necessary Or Not, COVID Booster Shots Are Probably On The Horizon
Booster shots are likely to be here before long because of the outdated, 60-year-old basic standard the Food and Drug Administration uses to authorize medicines for sale.
Elisabeth Rosenthal
Why We May Never Know Whether The $56,000-A-Year Alzheimer’s Drug Actually Works
Scientists may have to wait many years to find out whether Aduhelm is actually effective because the drug was approved using FDA's accelerated pathway.
Analysis: Why We’ll Likely Never Know Whether a COVID Lab Leak Happened in China
China has great scientists, but they work for an authoritarian government where politics always comes first, making it dangerous to reveal something that makes China look bad.
Telemedicine Is a Tool — Not a Replacement for Your Doctor’s Touch
Many of the new types of telemedicine being promoted by start-ups more clearly benefit providers’ and investors’ pockets, rather than yielding more high-quality and cost-effective medicine for patients.
Analysis: How the US Invested in the War on Terrorism at the Cost of Public Health
After 9/11, the United States rapidly shifted resources to create a massive infrastructure to ferret out and combat terrorism while forgetting that terrorism of nature can be equally deadly.
With Demand Far Exceeding Supply, It Matters That People Are Jumping the Vaccine Line
The Biden administration’s much-needed national strategy to end the covid-19 pandemic includes plans to remedy the chaotic vaccination effort with “more people, more places, more supply.”
Analysis: Some Said the Vaccine Rollout Would Be a ‘Nightmare.’ They Were Right.
There are already signs that distribution of the COVID vaccines will be messy, confusing and chaotic.
Take It From an Expert: Fauci’s Hierarchy of Safety During COVID
The nation's top infectious disease expert says he's reluctant to support a national mask mandate because that would mean that authorities would have to enforce it and that would be difficult to do.
Analysis: How A COVID-19 Vaccine Could Cost Americans Dearly
Given the prevailing business-centric model of American drug pricing, a COVID-19 vaccine could be budget breaking, perhaps making it unavailable to many.
Pages
